Highlights Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Delayed Nasdaq Other stock markets 20:11:45 16/05/2024 BST			5-day change	1st Jan Change
0.82 ^USD	-2.38%		-0.61%	+43.86%

05-14	Viracta Therapeutics Appoints Michael Faerm CFO	MT
05-14	Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	04-15	CI
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	04-01	CI
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	03-21	MT
North American Morning Briefing : Inflation -2-	03-15	DJ
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Viracta Therapeutics, Inc. Provides Clinical Update	01-04	CI
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels	12-04	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Viracta Therapeuticsâ€™ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma	28/06/23	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/03/23	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	13/03/23	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/03/23	CI
Viracta's Lymphoma Drug Candidate Granted European Commission's Orphan Drug Designation	19/01/23	MT
Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives	08/01/23	CI
Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients	30/11/22	CI
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Highlights

Filters